StudyFinder



Search Results Within Category "Arthritis & Rheumatic Diseases"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories
8 Study Matches

An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis (BMS Protocol IM101240)

The objective of this study is to create an international registry with long-term follow-up to characterize and evaluate the safety of abatacept in juvenile idiopathic arthritis (JIA). The primary objective of the JIA registry is to describe the long-term safety of abatacept treatment for JIA by quantifying the incidence rates of serious infections, autoimmune disorders, and malignancies.

Colleen Correll
All
up to 17 Years old
N/A
This study is NOT accepting healthy volunteers
NCT01357668
1403M48721
Show full eligibility criteria
Hide eligibility criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:

• Diagnosis of JIA (any subtype)
• Age < 18 years at the time of enrollment unless currently or previously enrolled in an abatacept clinical trial and received abatacept
• Receiving Abatacept at the time of enrollment as per treating physician's decision or received abatacept in a clinical trial
• Parent or legally acceptable representative willing to participate in the study and sign the informed consent
Exclusion Criteria:

• Pregnant or nursing female at the time of enrollment
• Prior malignancies if the patient has not been malignancy free for at least 5 years.
• Any serious acute or chronic medical condition other than JIA, including chronic infection, which would compromise the patient's ability to participate in the study
• Known poor compliance with clinic visits (based on physician judgment)
Juvenile Idiopathic Arthritis
I'm interested
Share via email
See this study on ClinicalTrials.gov

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

The primary objective for this observational study is to collect general and medical data from children, adolescents, and young adults who had pediatric onset rheumatic disease. This data will be used to evaluate the long-term safety and efficacy of therapeutic agents used to treat these diseases. This information will allow investigators to accurately report and follow changes in current medication use patterns and compare these to proposed standards and current treatment recommendations. The use of a single registry will allow for more analysis of the different therapeutic agents by allowing them to be compared to each other.

Colleen Correll
All
up to 21 Years old
N/A
This study is NOT accepting healthy volunteers
NCT02418442
1506M74443
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Onset of rheumatic disease prior to age 16 years for JIA and onset prior to age 19 years for all other rheumatic diseases (see appendix A).
• Subject (and/or parent/legal guardian when required) is able to provide written informed consent and willing to comply with study procedures.
• Subject and/or parent/legal guardian is willing to be contacted in the future by study staff.
Exclusion Criteria:

• Greater than 21 years of age at the time of enrollment.
Rheumatic Joint Disease
Systemic Arthritis, Oligoarthritis, Polyarthritis (Rheumatoid Factor Negative), Polyarthritis (Rheumatoid Factor Positive), Psoriatic Arthritis, Enthesitis Related Arthritis (ERA), Undifferianted Arthritis, CARRA Consensus Treatment Plans
I'm interested
Share via email
See this study on ClinicalTrials.gov

COG ALTE16C1 - Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma

PRIMARY OBJECTIVES: I. Determine whether infertility and/or biomarkers of spermatogenesis and steroidogenesis differ in male osteosarcoma survivors treated with cisplatin with or without ifosfamide compared to male controls without a history of cancer. II. Evaluate whether cisplatin with or without ifosfamide for the treatment of osteosarcoma alters sperm deoxyribonucleic acid (DNA) methylation. SECONDARY OBJECTIVES: I. Evaluate the role of genetic susceptibility in the development of impairments in spermatogenesis or steroidogenesis with contemporary regimens for the treatment of osteosarcoma. OUTLINE: Participants complete a health questionnaire over 30-45 minutes. Patients also provide saliva and semen samples and undergo collection of blood.

Karim Sadak
Male
18 Years to 50 Years old
NA
This study is NOT accepting healthy volunteers
NCT03206450
STUDY00004541
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Received upfront therapies for osteosarcoma, which included cisplatin, (with or without other agents)
• Patient must have completed cancer treatment >= 2 years prior to study enrollment
• Osteosarcoma survivors without a systemically treated relapse or subsequent malignancy
• Note: History of relapse or second malignancy is permitted if treated with local therapy only (e.g. surgery, radiation)
• Able to speak, read and write in English, French or Spanish
• All patients and/or their parents or legal guardians must sign a written informed consent
• All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Procedure: Biospecimen Collection, Other: Laboratory Biomarker Analysis, Other: Questionnaire Administration
Osteosarcoma
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain (SKOAP)

There is an urgent public health need to reduce our reliance on opioids for effective long-term pain management, particularly in knee osteoarthritis (KOA). This effectiveness trial will compare recommended treatments to reduce pain and functional limitations in KOA and identify clinical and patient-level factors associated with treatment response. These results will lead to improved patient selection for treatment and inform evidence based guidelines by offering well-tested, effective, non-opioid alternatives.

All
18 Years to 90 Years old
Phase 3
This study is NOT accepting healthy volunteers
NCT04504812
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Meets American College of Rheumatology Classification criteria for knee osteoarthritis
Exclusion Criteria:

• Any inability to complete study procedures, including, but not limited to low English language literacy.
• Unstable medical condition that presents as an absolute or relative contraindication for participation (e.g., unstable angina, poorly controlled diabetes mellitus, end stage renal failure, automated implantable cardioverter-defibrillator that cannot be disabled before RFA).
• Severe untreated bleeding disorder (anticoagulants may be continued during phase II treatments in most patients)
• Severe vision or hearing impairment or serious cognitive impairment that could interfere with consent or outcome assessment
• Poorly controlled serious psychiatric condition
• Active substance abuse
• Scheduled joint replacement on the affected knee
• History of unilateral total knee arthroplasty (TKA) with complaints of KOA pain limited to the operated knee
• Ulcers or an open wound in the region of the index knee
Drug: Duloxetine, Combination Product: Intra-Articular Injection, Procedure: Nerve Procedure with long acting blocks, Procedure: Nerve Procedure with nerve ablation, Behavioral: Pain Coping Skills Training, Other: Best Practices
Knee Osteoarthrosis
I'm interested
Share via email
See this study on ClinicalTrials.gov

Hmong Microbiome ANd Gout, Obesity, Vitamin C (HMANGO-C)

All
18 Years and over
N/A
This study is also accepting healthy volunteers
NCT04938024
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Self-identified Hmong persons whose both parents are Hmong, with and without hyperuricemia (serum urate (UA) ≥ 6.8 mg/dL ) and/or gout (defined by 2020 American College of Rheumatology Guideline for the Management of Gout) are eligible for the study.
• For those with gout, participants qualify if they have serum UA ≥ 6.8 mg/dL based on the baseline measurement or serum UA < 6.8 mg/dL based on the baseline measurement with at least 1 episode of peripheral joint or bursal swelling, pain, or tenderness (acute gout flare) in their lifetime, (with or without urate-lowering therapy)
Exclusion Criteria:

• Allergy or sensitivity to vitamin C
• Diagnosis/history of:
• Gastrointestinal surgery including colectomy, ileectomy, and gastrectomy
• Inflammatory bowel disease
• Auto-immune disease
• Type I diabetes mellitus
• Severe kidney disease (i.e., on dialysis)
• End-stage liver disease (i.e. cirrhosis)
• Glucose-6-phosphate dehydrogenase deficiency, (due to increased bleeding risk in those with G6PD deficiency when receiving vitamin C)
• Pregnant or breastfeeding persons
• Current use of:
• Antibiotics
• Probiotics supplement
• Ketogenic diet
Dietary Supplement: Vitamin C
Hyperuricemia, Gout
I'm interested
Share via email
See this study on ClinicalTrials.gov

UP0085: A POSTMARKETING, MULTICENTER, LONGITUDINAL, PROSPECTIVE, PHARMACOKINETIC, PHASE 1B STUDY IN PREGNANT WOMEN WITH CHRONIC INFLAMMATORY DISEASES TREATED WITH CIMZIA? (CERTOLIZUMAB PEGOL)

A postmarketing, multicenter, longitudinal, prospective, pharmacokinetic, phase 1B study in pregnant women with chronic inflammatory diseases treated with cimzia

Eugenia Shmidt
Phase IV
This study is NOT accepting healthy volunteers
NCT04163016
STUDY00009260
Digestive & Liver Health, Axial Spondyloarthritis, Crohn's Disease, Plaque Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis
inflammatory bowel disease, Axial Spondyloarthritis (AxSpA), CZP, Certolizumab Pegol, Cimzia, Clinics and Surgery Center (CSC), Crohn's Disease (CD), Pharmacokinetics, Plaque Psoriasis (PSO), Pregnant Women, Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA)
I'm interested
Share via email
See this study on ClinicalTrials.gov

A Phase 2 Study of Regorafenib in Combination with Nivolumab in Patients with Refractory or Recurrent Osteosarcoma Protocol Number: SARC038

This is a single arm, Simon two-stage historically controlled study to compare the 4-month progression-free survival rate of patients (≥ 5 years to ≤ 21 years of age) with relapsed/refractory osteosarcoma treated with regorafenib in combination with nivolumab to those who received regorafenib alone (historical control).

Brenda Weigel, MD, MSc
All
5 Years and over
Phase 2
This study is NOT accepting healthy volunteers
NCT04803877
STUDY00014546
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Age ≥ 5 years at the time of enrollment. Every effort will be made to ensure that 50% of patients will be ≤ 21 years of age.
• Confirmation by a pathologist of a diagnosis of localized or metastatic high grade osteosarcoma (excluding osteosarcoma associated with Paget disease of bone or extraskeletal osteosarcoma) that is recurrent or refractory after at least 1 prior line of systemic therapy in the neoadjuvant, adjuvant setting, or metastatic. For the purposes of this study, refractory is defined as progressive disease by RECIST 1.1 while on active therapy.
• Performance Status: Lansky (≤ 16 years of age) or Karnofsky (>16 years of age) performance score of ≥ 70, or Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1. See Appendix A. Patients who are unable to walk because of paralysis, but who are up and about in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
• At least one site of measurable disease on CT/MRI scan as defined by RECIST 1.1. Baseline imaging must be performed within 21 days of Day 1 of study therapy.
• Must be able to swallow intact pills
• Adequate organ and bone marrow function within 7 days of Day 1 of study therapy defined as:
• Absolute Neutrophil Count (ANC) ≥ 1000/mm3
• Platelets ≥ 75 000/mm3
• Hemoglobin ≥ 8 g/ dL (transfusions allowed)
• ALT and AST ≤ 3 x institutional upper limit of normal (ULN) or ≤ 5.0 x institutional ULN if considered due to tumor
• Serum albumin ≥ 3 g/dL
• Serum total bilirubin ≤ 1.5 x institutional ULN. NOTE: Patients with elevated bilirubin secondary to Gilbert's disease are eligible to participate in the study
• Serum creatinine ≤ 3 x institutional ULN or 24-hour creatinine clearance ≥ 30 ml/min (calculated creatinine clearance using Cockcroft formula is acceptable)
• Normal free T4. Replacement therapy allowed.
• Serum lipase ≤ 1.5 x ULN
• INR ≤ 1.5 x ULN
• Urine protein: Meets one of the following criteria: (i) urinary protein by urine dipstick is ≤ 100mg/dL or ≤ 2+ (ii) Urine Protein Creatinine(UPC) ratio <3.5 (iii) 24-hour urine protein was measured, urinary protein ≤ 3500 mg
• Adequate pulmonary function defined as:
• No evidence of dyspnea at rest
• No exercise intolerance due to pulmonary insufficiency
• Pulse Oximetry >92% on room air
• Adequate cardiac function defined as:
• QTc ≤ 480 msec
• Shortening fraction ≥ 27% by echocardiogram or ejection fraction ≥ 50% by gated radionuclide study or echocardiogram
• New York Heart Association Functional Classification Class I or II congestive heart failure (CHF).
• No clinically significant cardiac arrhythmias, stroke or myocardial infarction within 6 months prior to enrollment.
• Prior Therapy: All prior treatment-related toxicities must have resolved to ≤ Grade 1 or be determined clinically stable by the Investigator.
• Myelosuppressive chemotherapy: Patients must not have received myelosuppressive chemotherapy within 3 weeks of enrollment
• Hematopoietic growth factors: At least 7 days must have elapsed since the completion of therapy with a white blood cell or platelet growth factor. At least 14 days must have elapsed after receiving pegfilgrastim.
• Biologic (anti-neoplastic agent): At least 7 days must have elapsed since completion of therapy with a biologic agent.
• Monoclonal antibodies: At least 21 days must have elapsed since prior therapy that included a monoclonal antibody (e.g., dinutuximab, denosumab, bevacizumab).
• Radiotherapy: ≥ 2 weeks must have elapsed since local palliative XRT (small port); ≥ 3 months must have elapsed if prior craniospinal XRT was received, if ≥ 50% of the pelvis was irradiated, or if TBI was received; ≥ 6 weeks must have elapsed if other substantial bone marrow irradiation was given.
• Autologous Stem Cell Transplant or Rescue or Cellular Therapy: ≥ 2 months must have elapsed since transplant/cellular therapy.
• Voluntary, written informed consent
• Negative urine or serum pregnancy test in women of childbearing potential. Women of childbearing potential includes pre-menopausal girls with evidence of puberty onset, and adult women through the end of the first 2 years of the onset of menopause. Testing should be completed ≤ 7 days prior to Day 1 of study.
• Fertile men and women of childbearing potential must agree to use an effective method of birth control from Day 1 of study and for 5 months after last dose of nivolumab or for 8 weeks after last dose of regorafenib, whichever is longer.
• Effective methods of birth control include: surgical sterility (subject or subject's partner), barrier device (condom, diaphragm), contraceptive coil (IUD), abstinence, or oral contraception.
• Patients with central nervous system (CNS) disease are eligible if they have received prior radiotherapy or surgery to sites of CNS metastatic disease and are without evidence of progression for at least 4 weeks after CNS therapy.
Exclusion Criteria:

• Patients with prior or concurrent malignancy whose natural history or treatment does have the potential to interfere with the safety or efficacy assessment of the investigational regimen in this trial.
• Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol
• Major surgery (thoracotomy or laparotomy, etc.), laparoscopic biopsy, trauma within 28 days, or significant traumatic injury within 28 days prior to Day 1 of study or who have not recovered adequately from prior surgery
• Women who are pregnant or nursing/breastfeeding.
• Known hypersensitivity to excipients of the formulations of regorafenib or nivolumab or similar agents
• Inability to comply with protocol required procedures
• Patients with known active brain or leptomeningeal metastases
• Prior therapy with an immune checkpoint inhibitor or a tyrosine kinase inhibitor targeting VEGF
• Patients with autoimmune disease
• Chronic use of immunosuppressive therapies
• Received any investigational drug within 28 days of study enrollment
• Uncontrolled infection
• Known active HIV. Testing is not required. HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. However, strong CYP3A4 inhibitors are prohibited.
• Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
• Prior allogeneic hematopoietic stem cell/bone marrow transplant or solid organ transplant
• Uncontrolled hypertension defined as on average, > 140 systolic pressure or > 90 diastolic pressure in patient ≥ 18 y/o or > 95th percentile for age/gender in patients < 18 y/o despite medical management. If blood pressure is borderline, ensure patient is properly prepared (relaxed, sitting in chair for > 3 minutes), proper technique is used (correct cuff size and positioning), and document 2 separate recordings, each at least >5 minutes apart.
• History of clinically significant venous or arterial thrombotic or embolic event requiring systemic anticoagulation within 6 months of enrollment.
• Requirement of oral anticoagulant therapy with oral vitamin K antagonists (warfarin). Low-dose anticoagulants for maintenance of patency of central venous device or prevention of deep venous thrombosis is allowed. Therapeutic use of low molecular weight heparin or direct oral anticoagulants is allowed, providing the event prompting treatment occurred > 6 months prior. Subjects who are prophylactically being treated with an agent such as heparin will be allowed to participate, provided no prior evidence of underlying abnormality in coagulation parameters exists.
• Presence of non-healing wound, non-healing ulcer or fracture (excluding pathologic fracture)
• Pleural effusion or ascites that causes respiratory compromise (≥ CTCAE Grade 2 dyspnea)
• Significant currently active gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn's disease, malabsorption, or CTCAE Grade ≥ 2 diarrhea of any etiology
• Patients who require systemic corticosteroids (excluding temporary usage for tests, prophylactic administration for allergic reactions, or to maintain physiologic steroid levels for adrenal insufficiency) or immunosuppressants, or who have received such a therapy <14 days before enrollment
• Live/attenuated vaccine administered within 30 days of enrollment
• Patients receiving or requiring strong CYP3A4 inhibitors (e.g., clarithromycin, grapefruit juice, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifampin, St. John's wort)
• Any hemorrhage or bleeding event CTCAE ≥ Grade 3 within 28 days of study enrollment
• Body surface area (BSA) < 0.4 m2
Drug: Regorafenib 40 MG, Drug: Regorafenib 20MG, Drug: Nivolumab
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Osteosarcoma Metastatic
I'm interested
Share via email
See this study on ClinicalTrials.gov

Ultrasound Treatment for Rheumatoid Arthritis Study [ULTRA Study] (ULTRA)

The research objective is to demonstrate efficacy of spleen ultrasound stimulation in the treatment of rheumatoid arthritis (RA) in a pilot study. In particular, a new wearable ultrasound device has been developed for anti-inflammatory treatment by a company called SecondWave Systems. We will measure RA disease activity, biomarkers and clinical metrics during and after an 8-week course of spleen-directed daily ultrasound treatments.

Erik Peterson
All
18 Years and over
N/A
This study is NOT accepting healthy volunteers
NCT05417854
STUDY00016143
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Males and females ages 18 and above
• Must carry a diagnosis of rheumatoid arthritis, as defined by the American College of Rheumatology in 2010: (https://www.rheumatology.org/Portals/0/Files/2010_revised_criteria_classification_ra.pdf)
• Classification as ?definite RA? is based on the confirmed presence of synovial thickening in at least 1 joint, absence of an alternative diagnosis that better explains the synovitis, and achievement of a total score of 6 or greater (of a possible 10) from the individual scores in 4 domains: number and site of involved joints (score range 0?5), serologic abnormality (score range 0?3), elevated acute-phase response (score range 0?1), and symptom duration (2 levels; range 0?1)
• Exhibiting symptoms or signs of inadequate inflammatory disease control according to one of two measures: a. Multidimensional HAQ score of greater than 0.3 b. DAS-28-CRP greater than 3.2 (http://www.phusewiki.org/wiki/index.php?title=Disease_Activity_Score_-_CRP_(DAS-CRP)
• Candidate participant?s rheumatoid arthritis medical therapy should be stable for two weeks leading up to the study. Moreover, participants must be willing to maintain their current medication regimen throughout the study enrollment period (in adjunct to the additional investigational ultrasound treatment)
Exclusion Criteria:

• Active bacterial or viral infection
• Pregnant women or those trying to become pregnant
• Receiving active chemotherapy or immunotherapy to treat malignancy within 30 days prior to enrollment
• Having received Rituximab monoclonal antibody medication within 30 days prior to enrollment
• Presence of an implanted device
• Asplenia
• Splenomegaly
• Ascites
• Recent abdominal surgery
• Currently participating in an investigational drug or device study
• Open wound/sores near stimulation sites
• Inability to perform minimal daily self-cares associated with feeding/dressing, according to HAQ
• Any other clinical reasons deemed by the investigators of the study in which the patient would not be an appropriate candidate for the study
Device: Splenic Ultrasound
Rheumatoid Arthritis, Arthritis & Rheumatic Diseases, Immune Diseases
Rheumatoid Arthritis
I'm interested
Share via email
See this study on ClinicalTrials.gov